There is rather limited information on the interaction between the levels of mRNA genes encoding CD16a (FCGR3A) and CD16b (FCGR3B) in a tumor, and clinic and morphological factors determining a cancerous disease course including renal cancer. This evidence concerns the gene FCGR3A and renal carcinoma.